Aspire Biopharma Holdings, Inc.
ASBP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.85 | 38.82 | -3.36 | 0.00 |
| FCF Yield | -0.00% | -0.00% | -0.00% | -0.00% |
| EV / EBITDA | -697.81 | 3,256.86 | 9,348.82 | -241,767.61 |
| Quality | ||||
| ROIC | -48.30% | -6.84% | -0.33% | -4.80% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.20 | -0.15 | -0.42 | 9.63 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | 59.40% | 53.64% | -541,740.77% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -0.11 | 0.00 | -0.14 | -9.36 |
| Interest Coverage | 3.46 | -149.45 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |